List view / Grid view
![Lonza Logo on top of grey building in Basel, Switzerland [Credit: Taljat David / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Lonza-1-300x278.jpg)
![Lonza Logo on top of grey building in Basel, Switzerland [Credit: Taljat David / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Lonza-1-e1654774052980.jpg)
The PyroCell® Monocyte Activation Test - Human Serum System (PyroCell® MAT HS System) provides more sensitive detection of non-endotoxin pyrogen contaminants in pharmaceutical preparations.
![Scientist using scanner to read barcode - MODA-EM™ Paperless Solution [© Lonza, Basel]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Lonza-MODA-Solution-300x278.jpg)
![Scientist using scanner to read barcode - MODA-EM™ Paperless Solution [© Lonza, Basel]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Lonza-MODA-Solution-e1607446278766.jpg)
The UK’s Vaccines Manufacturing and Innovation Centre (VMIC) has selected Lonza’s MODA-EM™ Solution to digitise its Microbiology Quality Control operations. The MODA EM™ Platform will form a vital part of ongoing work that will support the VMIC coming online a year ahead of schedule.
Lonza Sales AG, through its Bioscience Division has joined forces with Sanquin Reagents B.V. to enable drug developers and quality control laboratories to take full advantage of the power of the Monocyte Activation Test (MAT).
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform.
Lonza Pharma & Biotech is the leader in capsule-based solutions and services, proudly offering Capsugel® products.
At Lonza Pharma & Biotech we provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need.
Learn how Adaptimmune, a leader in developing T cell cancer therapies, implemented Lonza’s MODA™ Solution to manage information in QC micro lab more efficiently.
LIMS requires a high degree of customization to meet QC Microbiology requirements. This means LIMS implementations often lock users into a functionality set that can’t accommodate technology advancements and regulatory changes without considerable investments, time, effort and money.
Given patient convenience and compatibility with a range of formulations and doses, capsule based dry-powder inhalation (DPI) technology is becoming the preferred DPI drug delivery platform for respiratory and systemic applications.
Comparative human in-vivo study of an immediate release tablet over-encapsulated by gelatin and hydroxypropyl methyl cellulose capsules –impact of dissolution rate on bioequivalence.
Lonza’s commitment to constant innovation and adding value to its customers and partners is today demonstrated by the launch of Ibex™ Solutions – a unique addition to its current offering...
Lonza is hosting a free 60-minute webinar on 25 April 2017 on how to create a compelling business case for the implementation of a paperless QC testing solution.
Lonza will hold a free 60-minute webinar on 2 November 2016 titled “LIMS and MODA-EM™ Solution – A Comprehensive Solution for Pharmaceutical Manufacturing Quality Control.”
Working in stem cell research can be both immensely rewarding and notoriously challenging. One of the most prominent challenges is taking what are often exciting new advances in stem cell biology made in the research lab, and translating these into viable, impactful therapies for patients.
BioWa, Inc. and Lonza today announced that they have entered into research agreements with Pfizer Inc. allowing the use of the POTELLIGENT® CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
